BioSig Technologies Files 10-Q for Q2 2025

TL;DR

BioSig 10-Q filed: shows preferred stock details as of 6/30/25. No major financial performance data here.

AI Summary

BioSig Technologies, Inc. filed its 10-Q for the period ending June 30, 2025. The company reported its financial position, including various series of preferred stock outstanding as of June 30, 2025, and December 31, 2024. Specific details on financial performance and operational highlights are not detailed in this excerpt.

Why It Matters

This filing provides a snapshot of BioSig Technologies' financial health and capital structure as of mid-2025, which is crucial for investors to assess the company's stability and potential.

Risk Assessment

Risk Level: medium — The filing is a standard 10-Q, but the lack of detailed financial performance metrics in this excerpt makes a definitive risk assessment difficult.

Key Numbers

• 20250630 — Reporting Period End (Indicates the end date for the financial data presented in the 10-Q.)
• 20241231 — Prior Period End (Provides a comparative financial point from the previous fiscal year-end.)

Key Players & Entities

• BioSig Technologies, Inc. (company) — Filer
• 20250630 (date) — Reporting Period End Date
• 20250815 (date) — Filing Date
• 0001530766 (company) — Central Index Key
• BSGM:SeriesCNinePercentageConvertiblePreferredStockMember (dollar_amount) — Preferred Stock Series

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
• $1 — 252,332 ) $ 17 $ 11 * - less than $1 The accompanying notes are an integra

Filing Documents

• form10-q.htm (10-Q) — 1502KB
• ex10-8.htm (EX-10.8) — 212KB
• ex31-1.htm (EX-31.1) — 10KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 7KB
• 0001641172-25-024455.txt ( ) — 9481KB
• bsgm-20250630.xsd (EX-101.SCH) — 78KB
• bsgm-20250630_cal.xml (EX-101.CAL) — 89KB
• bsgm-20250630_def.xml (EX-101.DEF) — 360KB
• bsgm-20250630_lab.xml (EX-101.LAB) — 600KB
• bsgm-20250630_pre.xml (EX-101.PRE) — 473KB
• form10-q_htm.xml (XML) — 1533KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION ITEM 1.

Financial Statements

Financial Statements Condensed consolidated balance sheets as of June, 2025 (unaudited) and December 31, 2024 3 Condensed consolidated statements of operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (unaudited) 4 Condensed consolidated statement of changes in stockholders' (deficit) equity for the three and six months ended June 30, 2025 and 2024 (unaudited) 5 Condensed consolidated statements of cash flows for the six months ended June 30, 2025 and 2024 (unaudited) 6 Notes to condensed consolidated financial statements (unaudited) 7-32 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33-38 ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 39 ITEM 4.

Controls and Procedures

Controls and Procedures 39

OTHER INFORMATION

PART II. OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 40 ITEM 1A.

Risk Factors

Risk Factors 40 ITEM 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities 41 ITEM 3. Defaults Upon Senior Securities 42 ITEM 4. Mine Safety Disclosures 42 ITEM 5. Other Information 42 ITEM 6. Exhibits 42

SIGNATURES

SIGNATURES 43 2 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS BIOSIG TECHNOLOGIES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In Thousands, Except Par Value and Share Amounts) June 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets: Cash $ 2,820 $ 142 Accounts receivable, net - 109 Sales tax receivable 18 - Due from related party 11 - Net investment in leases, short term - 13 Prepaid expenses and vendor deposits 152 80 Total current assets 3,001 344 Non-current assets: Property and equipment, net 53 85 Right-to-use assets, net 14 96 Net investment in leases, long term - 4 Other assets 44 44 Intangible assets, net 47,917 269 Goodwill 58,692 - Total non-current assets 106,720 498 Total assets $ 109,721 $ 842 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT Current liabilities: Accounts payable and accrued expenses, including $ 466 and $ 19 to related parties as of June 30, 2025 and December 31, 2024, respectively $ 7,572 $ 2,052 Derivative liability 105,498 - Dividends payable 115 110 Lease liability, short term 15 102 Total current liabilities 113,200 2,264 Total liabilities 113,200 2,264 Commitments and contingencies (Note 12) - - Mezzanine Equity Redeemable Series C 9% Convertible Preferred Stock, $ 0.001 par value, $ 1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; (liquidation preference of $ 105 ; cumulative dividends payable of $ 115 and $ 110 as of June 30, 2025 and December 31, 2024, respectively) 105 105 Stockholders' deficit: Preferred stock, $ 0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock. - - Common stock, $ 0.001 par value, authorized 200,000,000 shares, 30,793,135 and 17,239,096 issue

Business

Business and organization BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP Platform ("PURE EP"), that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. BioSig Technologies, Inc. was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the standard care in electrophysiology with our PURE EP System's enhanced signal acquisition, digital signal processing, and analysis during ablation of cardiac arrhythmias. The Company has generated minimal revenue to date and consequently its operations are subject to all risks inherent in business enterprises in early commercialization stage. On May 28, 2025, the Company completed the acquisition of Streamex Exchange Corporation (the "Acquisition"), pursuant to the Share Purchase Agreement dated as of May 23, 2025 (the "Merger Agreement") and amended on May 27, 2025 under the First Amendment to Share Purchase Agreement (the "Amendment") by and among the Company, BioSig Technologies, Inc., a Delaware corporation, BST Sub ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company ("ExchangeCo"), 1540875 B.C. Ltd., a company organized under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company ("Callco"), each shareholder of Streamex (each, a "Shareholder" and, collectively, the "Shareholders"), and 1540873 B.C. Ltd., a company organized under the laws of the Province of British Columbia, as trustee (the "Trustee") of the trust formed pursuant to the exchange rights agreement to be entered into between the Company, ExchangeCo, CallCo, and the Trustee (the "Exchange Rights Agreement"), the board of directors of the Company and Streamex.

Business

Business Acquisition The Company recognizes and measures identifiable tangible and intangible assets acquired and liabilities assumed as of the acquisition date at fair value. Fair value measurements require extensive use of estimates and assumptions, including estimates of future cash flows to be generated by the acquired assets. The operating results of the acquired business are included in our unaudited condensed consolidated financial statements beginning on the date of acquisition. The purchase price is equivalent to the fair value of consideration transferred. Goodwill is recognized for the excess of purchase price over the net fair value of assets acquired and liabilities assumed. Acquisition-related costs are expensed as incurred. Intangible Assets The Company intangible assets consist of trade name, developed technology, legal and compliance framework and patents. Trade name was recognized based on its distinct branding and expected contribution to future revenues. Developed technology was recognized for its proprietary protocols and systems enabling tokenization of real-world assets and its integration with decentralized finance platforms. Legal and compliance framework was recognized based on the cost to recreate the regulatory and legal infrastructure necessary for operations. The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company's U.S. Food and Drug Administration ("FDA") 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized patent costs are amortized to expense over the lesser of the legal patent term or the estimated life of the product of 20 years. Trade name was assigned a useful life of 10 years, developed technology was assigned a useful life of

View Full Filing

View this 10-Q filing on SEC EDGAR